Diligence memo · auto-generated · as of July 2, 2026

Ark Biotech Inc.

Ark Biotech Inc. looks fair against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Ark Biotech Inc. operates in Biotech, based in WESTWOOD.

Sub-sector tags: biotech.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Ark Biotech Inc. has raised $22M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $8.2M on 2024-05-10.

Most recent recorded round closed around 2024-05-10.

Valuation (modeled)modeled

Provath models Ark Biotech Inc. at approximately $46M (range $8.9M–$103M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.91× the median modeled value of Series A Biotech companies in 2022–2024 (12 peers) — value vs value, same stage and era. Within the normal band (91% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 10 months.

Last raise 2.1 yr ago; this sector typically re-raises about every 11 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round stepped up 1.6× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 91% of Biotech peers (233 compared).

Modeled value ranks above 81% of those peers.

Closest niche peers: Epsilon3, Inc., Salish Bioscience Inc., HB Biotech, Inc., Acoustic Wave Cell Therapy, Inc., Mindstate Design Labs, Inc..

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.